No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - JP Morgan has reiterated its 'overweight' rating on Croda International following strong third-quarter numbers from the speciality chemicals group.
The bank flagged a number of reasons for its "bullish view".
It said: "The earnings downgrade cycle is largely behind us, with consensus estimates likely to remain stable even as much of the sector faces further cuts; improved execution in OSG delivery, operating leverage and self-help cost actions; [and] the market's pessimism on business fundamentals, particularly regarding competitive pressures and portfolio commoditisation, seems excessive to us."
It concluded: "Notwithstanding some possible near-term growth headwinds in the pharma business from the recent US policy changes, there is significant mid-to-long-term earnings upside optionality from Croda's strong pipeline of customer projects across multiple pharma segments.
"Improved earnings delivery close to the sitting consensus should likely drive a step-by-step rerating of the shares."
On Thursday, Croda reiterated its full-year outlook after third-quarter sales were bolstered by strong performances in its consumer care and life sciences divisions.
As at 0900 BST, shares in the blue chip were trading 2% lower at 2,833p, amid difficult trading across the London market.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.